Karyopharm therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Newton, mass. , jan. 3, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the company granted stock options to purchase an aggregate of 24,300 shares of karyopharm's common stock and an aggregate of 16,600 restricted stock units (rsus) to four newly-hired employees.
KPTI Ratings Summary
KPTI Quant Ranking